Fig. 3From: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancerProbabilistic sensitivity analysis. Plot of incremental quality-adjusted life-years (QALYs) versus incremental cost from 1000 re-samplings varying all model parameters with probability distributionsBack to article page